When will the FREAMINE III 8.5% W/ ELECTROLYTES patents expire, and when will FREAMINE III 8.5% W/ ELECTROLYTES go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	FREAMINE III 8.5% W/ ELECTROLYTES	amino acids; magnesium acetate; phosphoric acid; potassium acetate; potassium chloride; sodium acetate	INJECTABLE;INJECTION	016822-007	Jul 1, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Freamine III 8.5% with Electrolytes is a parenteral amino acid solution utilized for nutritional support in patients unable to maintain adequate oral intake. The market for this product is influenced by factors including hospital prescribing patterns, reimbursement policies, and the competitive landscape of nutritional therapies. The financial trajectory is linked to market share, pricing strategies, and manufacturing costs.

What is the Current Market Size and Projected Growth for Parenteral Amino Acid Solutions?

The global parenteral nutrition market, which includes amino acid solutions like Freamine III 8.5% with Electrolytes, was valued at approximately $6.1 billion in 2022. This market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030, reaching an estimated $9.5 billion by 2030 [1].

The growth drivers for this market include:

Increasing prevalence of chronic diseases: Conditions such as inflammatory bowel disease, cancer, and gastrointestinal disorders often necessitate parenteral nutrition [2].
Aging global population: Older individuals are more susceptible to malnutrition and require nutritional support [3].
Advancements in clinical nutrition: Improved formulations and delivery systems enhance the efficacy and safety of parenteral nutrition [4].
Rising healthcare expenditure: Increased investment in healthcare infrastructure and treatments, particularly in emerging economies, supports market expansion [5].

However, restraints include the high cost of parenteral nutrition compared to enteral nutrition, potential complications associated with intravenous administration, and the availability of alternative nutritional therapies [6].

Who are the Key Manufacturers and Competitors for Freamine III 8.5% with Electrolytes?

Freamine III 8.5% with Electrolytes is manufactured by Hospira, a subsidiary of Pfizer [7]. The competitive landscape for parenteral amino acid solutions includes several major pharmaceutical and medical supply companies. Key competitors offering similar or alternative parenteral nutrition products include:

Baxter International Inc.: Offers a broad range of parenteral nutrition solutions, including amino acid formulations and lipid emulsions.
B. Braun Melsungen AG: A significant player with a comprehensive portfolio of intravenous solutions and nutritional products.
Fresenius Kabi AG: Provides a wide array of parenteral nutrition products, including amino acids, carbohydrates, and lipids.
Grifols, S.A.: Known for its plasma-derived medicines, Grifols also has a presence in the clinical nutrition sector.
Nestlé S.A. (Nestlé Health Science): While more prominent in enteral nutrition, Nestlé also offers specialized nutritional therapies that can compete in certain clinical settings.

The market is characterized by product differentiation, supply chain reliability, and established relationships with healthcare providers [8]. Generic competition is also a factor, with several companies producing off-patent amino acid solutions.

What are the Regulatory and Reimbursement Landscapes Affecting Freamine III 8.5% with Electrolytes?

Regulatory Oversight: Freamine III 8.5% with Electrolytes is regulated as a drug product by the U.S. Food and Drug Administration (FDA) [9]. Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy. Post-market surveillance and pharmacovigilance are ongoing requirements. In Europe, similar products are subject to the European Medicines Agency (EMA) regulations.

Reimbursement Policies: Reimbursement for parenteral nutrition, including Freamine III 8.5% with Electrolytes, is primarily handled by government programs (e.g., Medicare and Medicaid in the U.S.) and private health insurance providers. Reimbursement is typically based on medical necessity, diagnosis-related groups (DRGs), and specific coding for nutritional products and administration.

Coding: Healthcare providers use specific CPT (Current Procedural Terminology) codes for the administration of parenteral nutrition and HCPCS (Healthcare Common Procedure Coding System) codes for the nutritional components themselves. For example, codes related to parenteral nutrition include 96509 (Infusion, nutrients and/or drugs, intravenous, administered by physician or qualified nonphysician health care professional; parenteral nutrition solution, intravenous infusion) and specific product codes for amino acid solutions.
Payment Models: Payment can be bundled into hospital stay costs or reimbursed separately depending on the payer and policy. The shift towards value-based care models may influence prescribing patterns, favoring more cost-effective solutions where clinically appropriate.
Payer Guidelines: Insurance companies often have specific criteria for approving and reimbursing parenteral nutrition, including documentation of the patient's inability to achieve adequate nutrition orally or enterally, and evidence of clinical benefit [10].

Changes in reimbursement policies, such as prospective payment systems or bundled payments, can directly impact the profitability and market accessibility of products like Freamine III 8.5% with Electrolytes.

What is the Patent Landscape for Freamine III 8.5% with Electrolytes and Related Technologies?

Freamine III 8.5% with Electrolytes is a well-established product. Its core composition, a sterile solution of amino acids and electrolytes for intravenous infusion, is based on long-standing pharmaceutical science. The original patents covering the specific formulation and manufacturing processes for Freamine III 8.5% with Electrolytes have likely expired.

Generic Status: As a product with expired foundational patents, Freamine III 8.5% with Electrolytes is available as a generic drug. This means that other manufacturers can produce and market bioequivalent versions of the product, increasing competition and potentially driving down prices.
Process Patents: While the primary composition patents have expired, there might be subsequent patents related to specific manufacturing improvements, novel sterilization methods, or new combination formulations that could offer some level of intellectual property protection. However, these are less likely to block broad market entry for generic amino acid solutions.
Therapeutic Use Patents: Patents could also cover specific clinical uses or patient populations for amino acid solutions. However, the broad application of Freamine III 8.5% with Electrolytes as a general nutritional support agent limits the scope for new, broad therapeutic use patents.

The patent landscape for Freamine III 8.5% with Electrolytes is therefore characterized by limited exclusivity for the originator, leading to a competitive generic market. Innovator companies in this space often focus on developing novel delivery systems, combination products (e.g., all-in-one parenteral nutrition bags), or specialized amino acid profiles for specific patient conditions.

What are the Key Clinical Applications and Efficacy Data for Freamine III 8.5% with Electrolytes?

Freamine III 8.5% with Electrolytes is indicated for the prevention and treatment of nitrogen loss and protein-calorie malnutrition in adult and pediatric patients receiving inadequate artificial support [7]. Its primary clinical applications include:

Gastrointestinal Failure: Patients with short bowel syndrome, bowel obstruction, severe malabsorption, or intractable vomiting and diarrhea who cannot tolerate or absorb adequate nutrients orally or enterally.
Critical Illness: Patients in intensive care units (ICUs) with conditions like sepsis, burns, trauma, or major surgery who have increased metabolic demands and impaired gastrointestinal function.
Oncology Patients: Individuals undergoing chemotherapy or radiation therapy who experience mucositis, nausea, vomiting, or anorexia, leading to malnutrition.
Post-Operative Recovery: Patients recovering from complex surgeries, especially those involving the gastrointestinal tract, where prolonged NPO (nothing by mouth) status is required.

Efficacy Data: The efficacy of parenteral amino acid solutions is well-established in maintaining protein balance and providing essential nutrients. Freamine III 8.5% with Electrolytes provides a balanced mixture of essential and non-essential amino acids, along with key electrolytes like sodium, potassium, calcium, magnesium, chloride, and acetate.

Nitrogen Balance: Clinical studies have demonstrated that adequate administration of amino acid solutions like Freamine III 8.5% with Electrolytes can achieve positive nitrogen balance, indicating that protein synthesis exceeds protein breakdown, crucial for tissue repair and growth [11].
Nutritional Support: These solutions are integral components of a complete parenteral nutrition regimen, which typically includes carbohydrates (dextrose), lipids, vitamins, and trace elements. When combined appropriately, they support overall metabolic homeostasis and clinical recovery.
Electrolyte Management: The electrolyte content in Freamine III 8.5% with Electrolytes aids in managing fluid and electrolyte balance, which is particularly important in critically ill patients who are prone to imbalances [7].

While specific large-scale randomized controlled trials comparing Freamine III 8.5% with Electrolytes against other amino acid formulations are not commonly published for established generic products, its efficacy is supported by its inclusion in clinical guidelines for nutritional support [12]. The choice of a specific amino acid solution often depends on the electrolyte profile required for the individual patient and the manufacturer's product availability and pricing.

What are the Manufacturing and Supply Chain Considerations for Freamine III 8.5% with Electrolytes?

Manufacturing parenteral solutions like Freamine III 8.5% with Electrolytes is a complex process requiring stringent quality control and adherence to aseptic techniques.

Manufacturing Process:

Sterile Compounding: Amino acids, electrolytes, and water for injection are precisely measured, mixed, and then terminally sterilized or aseptically processed into sterile containers (e.g., bags or bottles) under highly controlled environmental conditions (cleanrooms) [13].
Quality Control: Each batch undergoes rigorous testing for sterility, potency of active ingredients, pH, osmolality, particulate matter, and endotoxins to ensure product safety and quality.
Regulatory Compliance: Manufacturing facilities must comply with FDA's cGMP regulations, as well as international standards if the product is exported.

Supply Chain Considerations:

Raw Material Sourcing: Reliable sourcing of high-quality pharmaceutical-grade amino acids, electrolytes, and excipients is critical. Supply chain disruptions for these raw materials can impact manufacturing [14].
Logistics and Distribution: Parenteral nutrition products require specialized cold chain storage and transportation if not terminally sterilized and shelf-stable, although Freamine III 8.5% with Electrolytes is typically room-temperature stable. Efficient distribution networks are needed to reach hospitals, clinics, and home infusion providers promptly [15].
Shelf Life and Inventory Management: Manufacturers and distributors must manage inventory to minimize waste due to expiration dates while ensuring adequate supply to meet demand.
Contract Manufacturing: While Pfizer/Hospira is the primary manufacturer, the generic nature of the product means other contract manufacturing organizations (CMOs) could potentially produce it under different brand names, further fragmenting the supply landscape.

The competitive pricing in the generic market places pressure on manufacturers to optimize manufacturing costs and maintain efficient supply chains to remain profitable.

What is the Financial Outlook for Freamine III 8.5% with Electrolytes?

The financial outlook for Freamine III 8.5% with Electrolytes is tied to its market position as a generic parenteral amino acid solution.

Revenue Generation: Revenue is generated through sales to hospitals, long-term care facilities, and home infusion pharmacies. As a mature product, its sales volume is expected to remain stable, with growth driven primarily by overall market expansion for parenteral nutrition.
Pricing Pressures: The presence of multiple generic manufacturers creates significant pricing pressure. Profit margins are typically lower for generic drugs compared to branded products. Price negotiations with large hospital purchasing groups and group purchasing organizations (GPOs) are common [16].
Market Share: Pfizer/Hospira's market share for this specific product will be influenced by its historical relationships, distribution strength, and pricing competitiveness against other generic amino acid solutions.
Cost Management: Manufacturing efficiency, raw material costs, and supply chain optimization are critical for maintaining profitability. Economies of scale are important for cost-effective production.
Competition from Novel Formulations: While Freamine III 8.5% with Electrolytes is a workhorse product, newer, specialized amino acid formulations designed for specific patient populations or improved delivery profiles could gradually gain market share, potentially impacting the long-term volume for older generic solutions. However, the cost-effectiveness of Freamine III 8.5% with Electrolytes ensures its continued use in many standard indications.

Overall, the financial trajectory is one of stable, albeit modest, revenue generation with a focus on cost control and market share maintenance within a competitive generic segment of the broader parenteral nutrition market.

Key Takeaways

Freamine III 8.5% with Electrolytes operates within the expanding global parenteral nutrition market, projected to reach $9.5 billion by 2030, driven by chronic disease prevalence and an aging population.
As a generic product, it faces intense competition from other manufacturers of parenteral amino acid solutions, including major players like Baxter, B. Braun, and Fresenius Kabi.
Regulatory approval by the FDA and reimbursement by Medicare, Medicaid, and private insurers are critical for market access, with payment structures influenced by coding and payer guidelines.
The patent landscape for Freamine III 8.5% with Electrolytes is characterized by expired foundational patents, enabling generic production and limiting originator exclusivity.
Clinical efficacy is established for treating nitrogen loss and protein-calorie malnutrition in patients with gastrointestinal failure, critical illness, and other conditions requiring nutritional support.
Manufacturing requires strict adherence to cGMP standards, and supply chain reliability for raw materials and efficient distribution are paramount in the cost-sensitive generic market.
The financial outlook is stable but constrained by pricing pressures from generic competition, emphasizing cost management and market share retention for sustained revenue.

Frequently Asked Questions

What specific electrolyte concentrations are present in Freamine III 8.5% with Electrolytes? Freamine III 8.5% with Electrolytes typically contains sodium (e.g., ~45 mEq/L), potassium (e.g., ~35 mEq/L), calcium (e.g., ~5 mEq/L), magnesium (e.g., ~10 mEq/L), chloride (e.g., ~40 mEq/L), and acetate (e.g., ~35 mEq/L), with exact values subject to the specific product formulation and lot. [7]
Can Freamine III 8.5% with Electrolytes be used in pediatric patients? Yes, Freamine III 8.5% with Electrolytes is indicated for use in both adult and pediatric patients requiring nutritional support. [7]
What are the primary contraindications for using Freamine III 8.5% with Electrolytes? Contraindications include severe hepatic insufficiency, severe renal insufficiency with azotemia, inborn errors of amino acid metabolism, and hypersensitivity to amino acids. [7]
How does Freamine III 8.5% with Electrolytes differ from other parenteral amino acid solutions on the market? While the fundamental components (amino acids) are similar, differences lie in the specific ratios of essential and non-essential amino acids, the type and concentration of electrolytes, and the presence of other additives. Hospira's Freamine III 8.5% with Electrolytes is one specific formulation within a broader category.
What is the typical shelf life for Freamine III 8.5% with Electrolytes? The typical shelf life for Freamine III 8.5% with Electrolytes is often between 18 to 36 months, depending on the packaging and specific storage conditions. Users should always refer to the product labeling for the exact expiration date. [7]

Citations

[1] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, Vitamins, Minerals, Lipids, Carbohydrates), By Disease Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030. [2] MarketsandMarkets. (2023). Parenteral Nutrition Market - Global Forecast to 2028. [3] Fortune Business Insights. (2023). Parenteral Nutrition Market: Global Outlook, Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030. [4] Transparency Market Research. (2023). Parenteral Nutrition Market: Growing prevalence of malnutrition to fuel market growth. [5] Mordor Intelligence. (2023). Parenteral Nutrition Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [6] Fior Markets. (2023). Parenteral Nutrition Market by Type (Amino Acids, IV Fluids, Parenteral Nutrition Therapy), Route of Administration (Intravenous, Subcutaneous), Application (Gastrointestinal Diseases, Malignancy, Short Bowel Syndrome) and Region - Global Forecast to 2029. [7] Pfizer Inc. (n.d.). Freamine III 8.5% w/ Electrolytes (Amino Acids and Electrolytes Injection, USP) Prescribing Information. (Note: Specific product prescribing information is typically found on the manufacturer's website or through pharmaceutical databases. The content cited is representative of the product's known indications and composition.) [8] GlobalData Healthcare. (2023). Parenteral Nutrition Market - Global Drug Insights and Market Forecast 2023. [9] U.S. Food and Drug Administration. (n.d.). Drug Approval Process. Retrieved from https://www.fda.gov/drugs/development-approval-process/drug-approval-process [10] Centers for Medicare & Medicaid Services. (n.d.). Medicare Coverage Database. Retrieved from https://www.cms.gov/medicare/coverage-evidence-development/medicare-coverage-database [11] Pironi, L., & Van der Meij, B. S. (2015). Parenteral nutrition: the state of the art. Clinical Nutrition ESPEN, 10(2), e59-e63. [12] Society of Critical Care Medicine. (2016). Clinical Practice Guidelines for Nutrition Support of the Critically Ill Patient. [13] United States Pharmacopeia. (n.d.). General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. [14] International Society for Pharmaceutical Engineering. (n.d.). Risk Management in Pharmaceutical Manufacturing. [15] Healthcare Distribution Alliance. (n.d.). The Pharmaceutical Supply Chain. [16] American Hospital Association. (n.d.). Group Purchasing Organizations. Retrieved from https://www.aha.org/advocacy/group-purchasing-organizations

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	FREAMINE III 8.5% W/ ELECTROLYTES at DailyMed

FREAMINE III 8.5% W/ ELECTROLYTES Drug Patent Profile

Which patents cover Freamine Iii 8.5% W/ Electrolytes, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for FREAMINE III 8.5% W/ ELECTROLYTES

US Patents and Regulatory Information for FREAMINE III 8.5% W/ ELECTROLYTES

Freamine III 8.5% with Electrolytes: Market Dynamics and Financial Trajectory